When using GLP-1 medications, you might experience several benefits including a notable reduction in body weight, decreased appetite, improved blood sugar levels, and even some cardiovascular advantages such as a reduced risk of heart attack and stroke in certain individuals
Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.[1][2] It has a molecular weight of approximately 4,800 Da and is administered subcutaneously, with a half-life supporting once-weekly dosing.[3][4] Developed by Eli Lilly, it is currently in Phase 3 clinical trials for obesity and type 2 diabetes (T2D), showing potential for superior weight loss compared to existing therapies.[1][5] Key characteristics for compounding pharmacies include: Multi-Receptor Agonist : Combines actions of GIP, GLP-1, and glucagon for enhanced metabolic effects.[1][6] Lyophilized Form : Supplied as a stable powder for reconstitution, similar to other peptides.[7][8] Versatile Delivery : Primarily subcutaneous, but potential for customized formulations in research contexts.[7][9] This makes Retatrutide a candidate for specialized preparations in compounding settings, though regulatory restrictions apply
Plan your second month with your PlexusDx clinician to discuss dose adjustments, side effect tolerance, and any dietary changes needed
Animal studies have shown thyroid C-cell tumours with some GLP-1 receptor agonists, though human relevance remains uncertain
All fats except the medium chain fats in coconut oil require L-Carnitine as a carrier to get them into the mitochondria, the energy-producing centers of cells where they can be burned as an energy source
Nicotinamide N-Methyltransferase: More than a vitamin B3 clearance enzyme (in Eng)
